Publication of Prospectus

Dechra Pharmaceuticals PLC
13 December 2007


NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY, IN OR INTO, THE UNITED STATES, CANADA, JAPAN, MALAYSIA, NEW ZEALAND,
SOUTH AFRICA OR AUSTRALIA OR INTO ANY JURISDICTION WHERE TO DO SO WOULD BREACH
ANY APPLICABLE LAW.


Date: Thursday, 13 December 2007

                                                           FOR IMMEDIATE RELEASE


                     Dechra Pharmaceuticals PLC ('Dechra')
                           PUBLICATION OF PROSPECTUS

Further to the announcement made yesterday, Dechra announces that the
Prospectus, in connection with the acquisition of VetXX Holding A/S and Placing
and Open Offer of 11,624,544 New Ordinary Shares at 303 pence per share on an 11
for 50 basis to raise approximately £35 million (before expenses), is being
posted today.

Dechra shareholders (subject to certain exceptions) will be mailed the
Prospectus (which includes notice of an Extraordinary General Meeting to be held
at 10:30 a.m. on 8 January 2008), an application form (for Dechra shareholders
holding shares in certificated form only) in connection with the acquisition and
Placing and Open Offer and a Form of Proxy in respect of the Extraordinary
General Meeting.

Copies of the Prospectus and Form of Proxy will be available in due course from
the Company's website at www.dechra.com and will be available for inspection
during normal business hours on Monday to Friday each week (public holidays
excepted) from and including the date of publication of the Prospectus until 8
January 2008, at the registered office of Dechra at Dechra House, Jamage
Industrial Estate, Talke Pits, Stoke-on-Trent, ST7 1XW. Copies of the Prospectus
will be made available free of charge upon request.

In addition, the Prospectus and Form of Proxy will shortly be available for
inspection at the UK Listing Authority's Document Viewing Facility at the
Financial Services Authority, 25 North Colonnade, Canary Wharf, London, E14 5HS.

Contacts:
Dechra Pharmaceuticals PLC                             Tel: [phone]
Ian Page, Chief Executive
Simon Evans, Group Finance Director

Dresdner Kleinwort Limited
(Joint financial adviser, Sponsor                      Tel: [phone]
and Broker to Dechra)
Jonathan Roe, Managing Director
Christian Littlewood, Director
Chris Treneman, Managing Director

NM Rothschild Limited
(Joint financial adviser to Dechra)                    Tel: [phone]
Lynn Drummond, Managing Director

Citigate Dewe Rogerson (PR advisers)                   Tel: [phone]
Fiona Tooley, Director

Dresdner Kleinwort Limited, which is authorised and regulated by the Financial
Services Authority, is acting as financial adviser, sponsor and broker to Dechra
and for no-one else in connection with the contents of this announcement and
will not be responsible to anyone other than Dechra for providing the
protections afforded to clients of Dresdner Kleinwort Limited, or for affording
advice in relation to the contents of this announcement or any matters referred
to herein.

N M Rothschild & Sons Limited, which is authorised and regulated by the
Financial Services Authority in the United Kingdom, is acting as financial
adviser to Dechra and no one else in relation to the transaction and will not be
responsible to anyone other than Dechra for providing the protections afforded
to clients of N M Rothschild & Sons Limited nor for providing advice in relation
to the proposed transaction.

This announcement does not constitute an offer to sell or the solicitation of an
offer to acquire or subscribe for New Ordinary Shares and/or to take up any 
entitlements.  The offer to acquire New Ordinary Shares pursuant to the proposed 
Open Offer will be made solely on the basis of the information contained in the
Prospectus to be published in connection with the proposed Open Offer.

The information contained in this announcement is not for release, publication
or distribution to persons in the United States, Canada, Japan, Malaysia,
New Zealand, South Africa or Australia or in any jurisdiction where to do so would 
breach any applicable law.This announcement is not an offer of securities for
sale in, into or from the United States, Canada, Japan, Malaysia, New Zealand,
South Africa or Australia. The New Ordinary Shares have not been and will not be
registered under the US Securities Act of 1933 (as amended) or under any relevant
securities laws of any  state or other jurisdiction of the United States, and will
not qualify for distribution under any of the relevant securities laws of
Canada, Japan, Malaysia, New Zealand, South Africa or Australia.  Accordingly,
the New Ordinary Shares may not be offered, sold, taken up, exercised, resold,
renounced, transferred or delivered, directly or indirectly, within the
United States (absent registration or an applicable exemption from registration) 
or within Canada, Japan, Malaysia, New Zealand, South Africa or Australia.

The availability of the Placing and Open Offer to persons who are not resident
in the United Kingdom may be affected by the laws of the relevant jurisdictions 
in which they are located.  Persons who are not resident in the United Kingdom 
should inform themselves of, and observe, any applicable requirements.



                      This information is provided by RNS
            The company news service from the London Stock Exchange